Supriya Chakraborty might have been studying insects in a lab had it not been for an immunology college instructor in India who taught him about the superheroes inside him—immune cells that wage a ...

Senolytics—a class of drugs that reduce chronic inflammation and tissue damage in aging cells—are shown to eliminate 30% to 70% of "zombie" cells in the body. These zombie cells, known as senescent ...

The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PH Lanifibranor was observed to decrease portal pressure by ...

An international research group has examined how many people are affected by preclinical and clinical obesity and what health ...

A potential breakthrough in the treatment of type 1 mediated chronic inflammatory skin diseases (ISD) has emerged, as ...

An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers.

The hormone estrogen regulates binge drinking in females, causing them to 'pregame' -- consume large quantities of alcohol in the first 30 minutes after it's offered, according to a preclinical study.

CollPlant Biotechnologies, a regenerative medicine firm focused on bioprinting of tissues and organs, has partnered with 3D-printing technology company Stratasys on a preclinical study involving ...

Hoth Therapeutics Inc. HOTH on Tuesday revealed preclinical data from its study on glial cell-derived neurotrophic factor ...

In a multi-institutional study published today in Nature Nanotechnology, researchers from The University of Texas MD Anderson Cancer Center reported that engineered bispecific nanobodies successfully ...

LOS ANGELES--(BUSINESS WIRE)--Laekna (2105.HK) announced today that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the ...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases ...